U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H4NO2.Fe.2ClH
Molecular Weight 276.884
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS BISGLYCINATE HYDROCHLORIDE

SMILES

Cl.Cl.[Fe++].NCC([O-])=O.NCC([O-])=O

InChI

InChIKey=JTLXXRNVKWTJHD-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.2ClH.Fe/c2*3-1-2(4)5;;;/h2*1,3H2,(H,4,5);2*1H;/q;;;;+2/p-2

HIDE SMILES / InChI

Molecular Formula C2H4NO2
Molecular Weight 74.0587
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
PubMed

PubMed

TitleDatePubMed
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.
1932 Jul 1
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932 Nov 11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932 Sep 30
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.
1937 Jul
[Ferrous lactate as an oral iron preparation for therapeutic use].
1954 Nov 27
Clinical appraisal of drugs with special reference to a new chelate hematinic.
1957 Jul 11
[FERROUS ASPARTATE IN THERAPY].
1964 Jan 1
[Historical notes on the therapy of depression].
1986 Nov 22
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.
1997 Oct
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
2007
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.
2009
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.
2010 Dec
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011 Jun 10
Tolerability of different oral iron supplements: a systematic review.
2013 Apr
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.
2013 Jul
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.
2015 Jun 22
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017 Jul 5
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.
2017 Mar 13
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.
2017 May 1
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:16:14 GMT 2023
Edited
by admin
on Fri Dec 15 17:16:14 GMT 2023
Record UNII
IW3QLZ8MRC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERROUS BISGLYCINATE HYDROCHLORIDE
Common Name English
IRON II BISGLYCINATE HYDROCHLORIDE
Common Name English
IRON (2+) BISGLYCINATE HYDROCHLORIDE
Systematic Name English
FERRATE(2-), DICHLOROBIS(GLYCINATO-N,O)-, DIHYDROGEN
Common Name English
FERROUS BISGLYCINATE HCL
Common Name English
IRON BISGLYCINATE HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
CAS
67972-33-2
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY
DRUG BANK
DBSALT001597
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY
RXCUI
1306114
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID60218169
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY
DAILYMED
IW3QLZ8MRC
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY
PUBCHEM
11414732
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY
FDA UNII
IW3QLZ8MRC
Created by admin on Fri Dec 15 17:16:14 GMT 2023 , Edited by admin on Fri Dec 15 17:16:14 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY